Cabotegravir found effective in offering protection against HIV


Arua, Uganda | THE INDEPENDENT | Injectable HIV drug cabotegravir has been found effective in offering protection against the disease if taken by HIV negative person as a form of Pre-Exposure Prophylaxis (PrEP).

In a large scale study code-named HPTN 083 that has been halted because of the coronavirus pandemic, a bi-monthly injection was found to be safe and effective in preventing infection among cisgender men and transgender women who have sex with men.

The study was conducted among 4,500 participants at sites in the Americas, Asia and South Africa. While this study will continue after the pandemic, this efficacy data was revealed after a review by the study Data and Safety Monitoring Board (DSMB) who also recommended that instead of some study participants being given a placebo (a medicine-less mimic of the drug), they should now be told that they will either be given cabotegravir or the oral drugs combination of Tenofovir/ Emtricitabine (TDF/FTC) and Truvada to compare efficacy.

According to a statement released on Monday by the HIV Prevention Trials Network (HPTN), cabotegravir lowered HIV incidence among the participants.

“Demonstrating conclusively that long-acting injectable cabotegravir is highly effective almost two years earlier than originally expected is exciting news”, said HPTN 083 protocol chair Raphael J Landovitz, “Its inspiring that we may soon have additional HIV prevention options for at risk individuals who have difficulty with or prefer not to take pills”.

Overall, the study that started in December 2016, enrolled 4,570 cisgender men and transgender women in South Africa, Vietnam, Peru, Brazil, Argentina, the US and Thailand among others. Two-thirds of the study participants were under 30 years of age.

A total of 50 incident HIV infections occurred with 38 happening to those that were taking oral PrEP and 12 were enrolled on cabotegravir, in other words approximately three times the number of incident infections by those on oral treatment.

Now, as soon as they resume the study, the statement notes that participants will be informed about what drug they were enrolled on initially and those on oral treatment will be shifted to the injectable. Those that were receiving the injectable will continue with it.

“Until we have a safe and effective vaccine for HIV, we must continue to find innovative prevention strategies”, said Myron Cohen, the Co-Principal Investigator of the study adding that increasing the number of options for prevention will give people a choice of what works best for them.

However, a sister study HPTN 084 which exclusively enrolled women on the injectable drug is on-going. Uganda is among the participating countries.



Football news:

Borussia have notified Manchester United that they will not release Sancho for less than 120 million euros. There are no other candidates
Agent Hakimi: Zidane is the reason for moving to Inter. He did not call Ashraf, but Conte spoke about the project
Neymar has agreed with PSG that he will be released if Barcelona make an offer (As)
Wigan collapsed under external control. Perhaps all because of the murky betting in the Philippines
Pep on Manchester City's European Cup ban: I'm Sure we will be allowed to play in the Champions League
Defender Athletic Berchiche: Real Madrid have the best squad in the world
Ronaldo scored the 25th goal of the Serie A season (from a free kick!). There have not been such bombers in Juve for 59 years